SG-001
- Generic Name
- SG-001
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
Phase 1
- Conditions
- Advanced Solid TumoursCervical CancerMalignant MesotheliomaLymphomaNon-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 192
- Registration Number
- NCT03852823
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath